Tags : Reports Results

Novartis Reports Results of QMF149 in P-III PALLADIUM Study for

Tuba Khan December 6, 2019

Shots: The P-III PALLADIUM study involves assessing of QMF149 [indacaterol acetate + mometasone furoate (IND/MF)] vs mometasone furoate (MF) as monothx. in 2,216 asthma patients with medium or high dose […]readmore

Tags : Reports Results

Novartis Reports Results of QMF149 in P-III PALLADIUM Study for

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Reports Results

Novartis Reports Results of QMF149 in P-III PALLADIUM Study for

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company